Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001703406 | SCV005411340 | uncertain significance | not provided | 2023-10-18 | criteria provided, single submitter | clinical testing | BP4 |
Ambry Genetics | RCV004897687 | SCV005559839 | uncertain significance | not specified | 2024-08-14 | criteria provided, single submitter | clinical testing | The c.983C>T (p.T328I) alteration is located in exon 6 (coding exon 6) of the CFHR4 gene. This alteration results from a C to T substitution at nucleotide position 983, causing the threonine (T) at amino acid position 328 to be replaced by an isoleucine (I). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome Diagnostics Laboratory, |
RCV001703406 | SCV001931059 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV001703406 | SCV001957801 | likely benign | not provided | no assertion criteria provided | clinical testing |